Kala Pharmaceuticals Inc (KALA) Receives $21.50 Consensus Price Target from Analysts

Kala Pharmaceuticals Inc (NASDAQ:KALA) has received an average recommendation of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $21.50.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Jefferies Financial Group assumed coverage on Kala Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $15.00 price target for the company. Wedbush set a $51.00 price target on Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 14th. BidaskClub upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Finally, Oppenheimer assumed coverage on Kala Pharmaceuticals in a research report on Wednesday, April 24th. They set an “outperform” rating and a $11.00 price target for the company.

NASDAQ KALA traded up $0.09 during trading hours on Wednesday, hitting $5.92. The company had a trading volume of 102,503 shares, compared to its average volume of 209,841. Kala Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $16.00. The company has a quick ratio of 10.17, a current ratio of 10.30 and a debt-to-equity ratio of 0.86. The company has a market cap of $196.18 million, a P/E ratio of -2.40 and a beta of 1.64.



Kala Pharmaceuticals (NASDAQ:KALA) last issued its earnings results on Thursday, May 9th. The company reported ($0.75) EPS for the quarter, hitting the consensus estimate of ($0.75). The company had revenue of $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. Equities research analysts anticipate that Kala Pharmaceuticals will post -2.82 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of Kala Pharmaceuticals in the 1st quarter valued at approximately $41,000. Wellington Management Group LLP lifted its stake in shares of Kala Pharmaceuticals by 1.9% in the 1st quarter. Wellington Management Group LLP now owns 1,555,177 shares of the company’s stock valued at $12,860,000 after purchasing an additional 29,534 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Kala Pharmaceuticals in the 1st quarter valued at approximately $325,000. State of Wisconsin Investment Board lifted its stake in shares of Kala Pharmaceuticals by 30.0% in the 1st quarter. State of Wisconsin Investment Board now owns 15,600 shares of the company’s stock valued at $129,000 after purchasing an additional 3,600 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Kala Pharmaceuticals by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 286,184 shares of the company’s stock valued at $2,367,000 after purchasing an additional 30,424 shares during the last quarter. Hedge funds and other institutional investors own 67.92% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Further Reading: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.